Efficiency and Safety of Microwave Ablation Plus Immune Checkpoint Inhibitor for Patients With Multiple Primary Lung Cancer: A Open, Multi-center, Phase II Clinical Trial

NCT05053802 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

146

Enrollment

OTHER

Sponsor class

Conditions

Multiple Primary Lung Cancer

Interventions

COMBINATION_PRODUCT: Microwave ablation plus Camrelizumab
DEVICE: Microwave ablation

Sponsor

Shanghai Pulmonary Hospital, Shanghai, China